東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

FindBook

Google Book

Amazon

博客來

Feeling Evergreen: A Case Study of Humira's Patent Extension Strategies and Retroactive Assessment of Second-Line Patent Validity.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Feeling Evergreen: A Case Study of Humira's Patent Extension Strategies and Retroactive Assessment of Second-Line Patent Validity./
作者:	Campanelli, Gina.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2022,
面頁冊數:	103 p.
附註:	Source: Masters Abstracts International, Volume: 83-10.
Contained By:	Masters Abstracts International83-10.
標題:	Biology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29163424
ISBN:	9798426817500

Feeling Evergreen: A Case Study of Humira's Patent Extension Strategies and Retroactive Assessment of Second-Line Patent Validity.
Campanelli, Gina.

Feeling Evergreen: A Case Study of Humira's Patent Extension Strategies and Retroactive Assessment of Second-Line Patent Validity. - Ann Arbor : ProQuest Dissertations & Theses, 2022 - 103 p.

Source: Masters Abstracts International, Volume: 83-10.

Thesis (A.L.M.)--Harvard University, 2022.

This item must not be sold to any third party vendors.

The United States pharmaceutical landscape has been shifting considerably throughout the 21st century, resulting in higher drug costs and smaller new product pipelines. One factor is the increased prevalence of patent evergreening and patent thickets. Patent evergreening occurs when a manufacturer files additional patents based on modifications to an existing product to extend patent protection period. Patient thickets occur when a manufacturer files multiple overlapping patents on different components of the same product. One of the first products to capitalize on this system was Humira, a rheumatoid arthritis drug. Humira's manufacturer, AbbVie, has been granted over 130 patents, resulting in a market exclusivity period stretching from launch in 2002 until 2023. The aim of this investigation is to determine the impact of Humira's evergreening strategy on the rheumatoid arthritis market, and to conduct a patent validity assessment to aid in determining the social cost and impact of the additional years of exclusivity. This study analyzed Humira's patents and available clinical trial data to assess evergreening strategy and quantify patient benefit and assessed financial metrics to determine the additional financial benefit to AbbVie per additional year of exclusivity. This investigation shows that Humira increased evergreening tactics in an attempt to prevent biosimilar competition and that subsequent formulations provided marginal patient benefit. Additionally, AbbVie was able to decrease research expenditures each year while increasing Humira's list price. Ultimately, though this strategy was successful for Humira, it may not be replicable in the future due to evolving antitrust litigation.

ISBN: 9798426817500Subjects--Topical Terms:

522710
Biology.
Subjects--Index Terms:

Patent extension

Feeling Evergreen: A Case Study of Humira's Patent Extension Strategies and Retroactive Assessment of Second-Line Patent Validity.
LDR:02985nmm a2200397 4500 001 2347231
005 20220719070541.5
008 241004s2022 ||||||||||||||||| ||eng d
020 $a 9798426817500
035 $a (MiAaPQ)AAI29163424
035 $a AAI29163424
040 $a MiAaPQ $c MiAaPQ
100 1 $a Campanelli, Gina. $3 3686453
245 1 0 $a Feeling Evergreen: A Case Study of Humira's Patent Extension Strategies and Retroactive Assessment of Second-Line Patent Validity.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2022
300 $a 103 p.
500 $a Source: Masters Abstracts International, Volume: 83-10.
500 $a Advisor: Morris, James R.;Fisher, William W.
502 $a Thesis (A.L.M.)--Harvard University, 2022.
506 $a This item must not be sold to any third party vendors.
520 $a The United States pharmaceutical landscape has been shifting considerably throughout the 21st century, resulting in higher drug costs and smaller new product pipelines. One factor is the increased prevalence of patent evergreening and patent thickets. Patent evergreening occurs when a manufacturer files additional patents based on modifications to an existing product to extend patent protection period. Patient thickets occur when a manufacturer files multiple overlapping patents on different components of the same product. One of the first products to capitalize on this system was Humira, a rheumatoid arthritis drug. Humira's manufacturer, AbbVie, has been granted over 130 patents, resulting in a market exclusivity period stretching from launch in 2002 until 2023. The aim of this investigation is to determine the impact of Humira's evergreening strategy on the rheumatoid arthritis market, and to conduct a patent validity assessment to aid in determining the social cost and impact of the additional years of exclusivity. This study analyzed Humira's patents and available clinical trial data to assess evergreening strategy and quantify patient benefit and assessed financial metrics to determine the additional financial benefit to AbbVie per additional year of exclusivity. This investigation shows that Humira increased evergreening tactics in an attempt to prevent biosimilar competition and that subsequent formulations provided marginal patient benefit. Additionally, AbbVie was able to decrease research expenditures each year while increasing Humira's list price. Ultimately, though this strategy was successful for Humira, it may not be replicable in the future due to evolving antitrust litigation.
590 $a School code: 0084.
650 4 $a Biology. $3 522710
650 4 $a Business administration. $3 3168311
650 4 $a Patent law. $3 3168356
650 4 $a Pharmaceutical sciences. $3 3173021
653 $a Patent extension
653 $a Second-line patent validity
653 $a Drug costs
653 $a Patent evergreening
653 $a Antitrust litigation
690 $a 0306
690 $a 0310
690 $a 0505
690 $a 0572
690 $a 0562
710 2 $a Harvard University. $b Extension Studies. $3 3560717
773 0 $t Masters Abstracts International $g 83-10.
790 $a 0084
791 $a A.L.M.
792 $a 2022
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29163424